Enzon Pharmaceuticals, Inc.
ENZN
$0.04
-$0.01-13.33%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -- | -- | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -- | -- | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -100.00% | -- | -- | 0.00% |
| SG&A Expenses | 50.32% | 78.18% | 87.00% | 29.60% | 16.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.32% | 78.18% | 87.00% | 29.60% | 16.81% |
| Operating Income | -53.53% | -82.42% | -84.61% | -27.11% | -17.23% |
| Income Before Tax | -260.06% | -171.29% | -78.27% | -7.56% | 42.84% |
| Income Tax Expenses | 246.67% | 289.88% | 404.17% | 322.44% | -85.71% |
| Earnings from Continuing Operations | -258.34% | -183.83% | -104.41% | -43.34% | 47.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.34% | -183.83% | -104.41% | -43.34% | 47.20% |
| EBIT | -53.53% | -82.42% | -84.61% | -27.11% | -17.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1,561.76% | -916.28% | -700.00% | -607.69% | 206.25% |
| Normalized Basic EPS | -87.61% | -85.00% | -77.59% | -6.80% | 44.87% |
| EPS Diluted | -3,771.43% | -1,626.09% | -1,900.00% | -842.86% | 143.75% |
| Normalized Diluted EPS | -87.61% | -85.00% | -77.59% | -6.80% | 44.87% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -1.63% | -2.19% | -23.67% | 0.76% | -0.32% |